Matricelf Ltd. Logo

Matricelf Ltd.

Develops autologous, patient-specific tissue implants for regenerative medicine.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion

Description

Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Circio Holding ASA Logo
Clinical-stage company developing circular RNA medicines and immunotherapies.
Norway
CRNA
CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo
A cancer diagnostics developer creating a blood test for early lung cancer detection.
United Kingdom
CIZ
CJ Bioscience Logo
Develops microbiome therapeutics for oncology and IBD using an AI-powered platform.
South Korea
311690
Climb Bio, Inc. Logo
Clinical-stage biotech developing therapies for immune-mediated diseases.
United States of America
CLYM
CODEXIS, INC. Logo
A protein engineering company developing enzymes for therapeutics and life sciences.
United States of America
CDXS
COGNITION THERAPEUTICS INC Logo
Clinical-stage company developing oral therapeutics for neurodegenerative disorders.
United States of America
CGTX
Combigene AB Logo
A gene therapy company focused on neurological disorders and chronic pain.
Sweden
COMBI
Compugen Ltd. Logo
A clinical-stage company developing cancer immunotherapies using an AI platform.
Israel
CGEN
COMPUGEN LTD Logo
A clinical-stage company using AI to discover cancer immunotherapy drug targets.
United States of America
CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies and provides non-clinical CRO preclinical services.
South Korea
166480

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.